Posted on

Wuhan Announces Strategic Reorganization for Its Operational Advancement in the Medical Marijuana and Psilocybin Mushroom Therapy Markets

BARCELONA, Spain, Aug. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to announce a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company’s three primary growth strategies: optimizing the value of the core; increasing health and well-being product lines, and accelerating distribution of new business models.

“Throughout his tenure as CEO, Mr. Kamaneh was instrumental in leading Wuhan in surpassing many milestones, and he has provided sound financial leadership to the Company,” said Jeffrey Robinson, newly appointed CEO. Mr. Kamaneh’s transition as Chief Financial Officer within the company only strengthens managements with his more than fifteen years of experience in finance and various manufacturing industries. Ramy brings a rare combination of expertise leading both public companies and private companies through significant stages of growth. At Wuhan, he will support the company’s next level of expansion by aligning corporate finance with all aspects of the business, from engineering and manufacturing to logistics and operations.

Mr. Robinson further comments: “The transformative joint-venture partnership between Wuhan and Biodelta served as a catalyst for us to re-examine how to best organize the company for increased emphasis on execution and profitable growth. This strategic reorganization focusing on each of our own core strengths, the integration of Wuhan and Biodelta, and long-term growth provide the right structure for us to optimize the value of our businesses today while creating future-oriented opportunities.”

“Mr. Robinson’s appointment and this transition are essential milestones in a succession plan that the board of directors has been working on for the past months,” says Ramy Kamaneh. “Mr. Robinson’s people-focused leadership style, industry expertise, and market understanding will build on the success of the Company. Mr. Robinson is focused on the future and guiding Wuhan in achieving its long-term strategic goals.”

Additionally, Mr. Luka Marjanovic is joining the Wuhan team as Head of Product Development for the MJ MedTech division In South Africa. This new appointment solidifies Wuhan’s core business operations.  Mr. Marjanovic is responsible for the development, implementation, enhancement and support of the Dr. AnnaRx™ and Medspresso™ products, and delivery channels. This includes conceptual stages through research, development, marketing, training, performance tracking and the entire product life cycle in support of Wuhan’s strategic goals and objectives.

Mr. Marjanovic is taking an integrative approach to build solutions and drive product development. “I’m excited to work with the team and to be given the opportunity to apply strategic practices that I’ve gained through my prior experience as we continue to improve our products, processes, and scaling of our operations. The speed, frequency, and timeline of product releases for the Dr. AnnaRx™ line are very impressive,” says Mr. Marjanovic. “We plan to have 30 products in the pipeline by year-end.”

About Luka Marjanovic, BSc., MSc. 

Mr. Marjanovic holds a Bachelor’s in International Business from Denmark and a Master’s in International Management from ESADE Business & Law School. During his undergraduate studies, he founded his own consulting firm, providing services to local businesses in various sectors; as well as working as a research assistant in the field of Big Data. Prior to his education, he served in the Danish Royal Army as Second Sergeant, leading and managing a group of men, under extreme pressures and conditions. Luka has spent significant time abroad, living and working in six different countries, and is now responsible for designing business models and go-to-market strategies for Dr. AnnaRx™ and Medspresso™ products.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for new Psilocybin therapies that will help patients who suffer from mental illness, Alzheimer and Parkinson disease. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board under the trading symbol “WUHN”.

For further information:
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the 

meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo

Posted on

Vireo Health to Present at the 39th Annual Canaccord Genuity Growth Conference

MINNEAPOLIS, Aug. 6, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced its participation at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 8, 2019.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Chief Executive Officer Kyle Kingsley, M.D., will present and meet with investors at the conference. Dr. Kingsley’s presentation will begin at approximately 8:00 a.m. ET (7:00 a.m. CT). An electronic copy of Dr. Kingsley’s presentation will be available in the investor relations section of Vireo’s website.

The Canaccord Genuity Growth Conference has become one of the industry’s premier investment industry conferences for companies and investors focused on growth. During this two-day event, leading companies and investors in the global growth universe will come together to share knowledge, discuss emerging trends, build relationships, identify opportunities, and ignite global ideas for growth. Investors interested in meeting with Vireo management at this event should contact their Canaccord representative.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-to-present-at-the-39th-annual-canaccord-genuity-growth-conference-300897023.html

SOURCE Vireo Health International, Inc.

Posted on

OTC Markets Group Welcomes Vireo Health International Inc. to OTCQX

NEW YORK, Aug. 2, 2019 /PRNewswire/ — OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Vireo Health International Inc. (CSE: VREO; OTCQX: VREOF), a leading cannabis company whose mission is to bring the best of medicine, engineering and science to the cannabis industry, has qualified to trade on the OTCQX® Best Market.

Vireo Health International begins trading today on OTCQX under the symbol “VREOF.”  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“We are pleased to welcome Vireo Health International to the OTCQX Best Market,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. “Along with their recent listing on the Canadian Securities Exchange in March and subsequent M&A transactions, trading on the OTCQX Market in the U.S. will enable Vireo Health to build stronger visibility and awareness across North America and provide investors with transparent trading. We look forward to supporting the company in the U.S. public market.”

MCAP LLC acted as Vireo Health International’s OTCQX sponsor.

About Vireo Health International Inc.
Vireo’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. The company’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The company is currently licensed in ten states including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, and Rhode Island.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Vireo Health Contacts:

Investor Inquiries
Sam Gibbons
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
albezakes@vireohealth.com
(267) 221-4800

Posted on

Vireo Health Subordinate Voting Shares Approved for Inclusion on the OTCQX® Best Market

Shares will begin trading under ticker symbol “VREOF” on August 2

MINNEAPOLIS, Aug. 1, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced that it has qualified to trade on the OTCQX® Best Market. Vireo will begin trading on August 2 on OTCQX under the symbol “VREOF.”

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Vireo first went public earlier this year, when it began trading on the Canadian Securities Exchange under the stock symbol “VREO”.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at www.otcmarkets.com/stock/VREOF/overview. MCAP LLC acted as Vireo Health International’s OTCQX sponsor.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the company, please visit www.vireohealth.com.

About OTC Markets Group Inc.
OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com   
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-subordinate-voting-shares-approved-for-inclusion-on-the-otcqx-best-market-300895343.html

SOURCE Vireo Health International, Inc.

Posted on

Vireo Health Files Patent for Multichannel Vaporizer

Company is developing a vaporizer that allows consumers to customize their experience by utilizing multiple cartridges in one device

MINNEAPOLIS, July 25, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO), a leading physician-led, science-focused multi-state cannabis company, today announced that the Company filed a patent application with United States Patent and Trademark Office (“USPTO”) for a multichannel vaporizer designed to hold at least two vaporizer cartridges. The device will allow a user to adjust the mixture of vapor coming from each cartridge using a simple interface.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

“Vireo Health is committed to helping consumers find their ‘cannabis sweet spot’ whether they are a connoisseur or a first-time user,” said Founder and CEO Kyle Kingsley, M.D. “When developed, in addition to potential medical benefits, we expect that the multichannel vaporizer will allow consumers to control and adjust their own experience or even create their own custom blends of different strains, terpene profiles, and flavors.”

Currently, if a consumer or patient wants to use more than one vaporizer formulation, he or she needs to purchase a separate vaporizer cartridge for each formulation. For example, if a user wanted the full spectrum of THC to CBD ratios that Vireo offers, the patient would have to purchase five different cartridges. The user would also need to purchase a separate battery for each cartridge or change out the cartridges every time he or she wanted to use a different formulation.

The multichannel vaporizer will be a single device that will allow a user to carefully change and control the desired effect for every inhalation. In one application­­ of the invention, the vaporizer would house a separate THC cartridge and CBD cartridge, thus enabling the user to adjust the THC to CBD ratio of the vapor to his or her preference in real time.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-files-patent-for-multichannel-vaporizer-300890975.html

SOURCE Vireo Health International, Inc.

Posted on

AbbVie is committed to the elimination of hepatitis C in Canada by 2030

  • Everyone has a part to play in making hepatitis C (HCV) elimination the next public health success
  • Partnerships are essential to solving some of the most pressing

 

MONTREAL (Quebec), July 25, 2019 – AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, supports a wide range of efforts to help elevate and prioritize hepatitis C (HCV) elimination because achieving the shared goal of elimination by 2030 will take more than medicine. It will take transparent and collaborative partnerships with healthcare professionals, governments and community organizations to remove barriers to care and to help simplify treatment options, especially for the Priority populations, which include people who inject or use drugs, as well as immigrants and newcomers to Canada.1

 

“HCV elimination starts with demonstrating our commitment to the World Health Organization 2030 goal,” explains Stéphane Lassignardie, General Manager, AbbVie Canada. “Through partnerships with stakeholders, we are working to find sustainable solutions that allow more patients to be screened, linked to care, and treated in a shorter period of time. We have engaged with governments across Canada to lower the price of hepatitis C treatments so that every patient cured accelerates the path to elimination. This is because we have a shared commitment and by working together, we can eliminate this disease.”

 

In Canada, an estimated 250,000 people are living with chronic hepatitis C but as many as 44% are not aware that they have it.1 Left undiagnosed and untreated, chronic hepatitis C can lead to cirrhosis, liver cancer or liver failure. Currently, hepatitis C is the leading indication for liver transplant in Canada.2 Of the people who inject drugs, 66% have past or current HCV infection. 1

 

Cool Aid Community Health Centre based in Victoria, British Columbia, provides integrated primary

health care services within a multidisciplinary team to treat illness and promote wellness. “Because HCV disproportionately affects marginalized populations in Canada, our nurse-led model for the treatment of HCV focuses on community outreach and intensive case management in order to successfully treat those living with HCV who require a high level of support. In addition, we work with the HCV treatment providers to develop education and awareness tools specific to this population,” says Tamara Barnett, Primary Care Nurse Clinician at Cool Aid Community Health Centre.

 

Up to 35% of all HCV infections in Canada are among immigrants and newcomers, especially those from countries where HCV is common.1 Although voluntary HCV screening after arrival in Canada is included in existing national recommendations, immigrants and newcomers are less likely to access the healthcare system than Canadian-born residents, and healthcare providers may be unaware of countries where HCV is common.1

 

“At the Jewish General Hospital, we see thousands of people on a yearly basis with a variety of liver diseases. A significant number of them are immigrants and newcomers. Hepatitis C is one of the common diseases that we find among this population. I must say that we have a great referral system with our local community health centres,” explains Dr. Nir Hilzenrat, Gastroenterologist and Hepatologist. “Today, we have the right treatments to eliminate hepatitis C, but if we are to reach the goal set by the World Health Organization, we need to work on prevention, as well as screening and linking to care people living with this disease. For me, it’s important to work with the Priority populations to educate them in order to remove any barriers and facilitate understanding so that they can be successfully treated and cured.”

 

Sunday, July 28, marks World Hepatitis Day. Ahead of this date, AbbVie held an HCV Awareness and Screening Day for its employees providing an opportunity to learn more about the disease and to get tested on a voluntary basis. On July 18, close to 30% of head office employees participated seeking to get answers to better understand the myths, facts and stigma surrounding this devastating and deadly disease.

 

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to

developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

###

Media:

Muriel Haraoui AbbVie Canada 514-717-3764

muriel.haraoui@abbvie.com

 

 

 

1 Canadian Network on Hepatitis C (CanHepC). Blueprint to inform hepatitis C elimination efforts in Canada. www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf. Accessed July 2019.

2 The Canadian Liver Foundation. www.liver.ca/how-you-help/advocate/. Accessed July 2019.

Posted on

Vireo Health CEO Kyle Kingsley, M.D. responds to U.S. Senate Committee on Banking, Housing and Urban Affairs Hearing on Challenges for Cannabis and Banking

VIEW ALL NEWS

Posted on

Vireo Health Launches New York’s First Same-Day Marijuana Delivery Service

With More than 25,000 Home Deliveries – Company Now Offers Free Same-Day Option

NEW YORK, July 16, 2019 /PRNewswire/ — Vireo Health of New York (“Vireo” or the “Company”), a subsidiary of Vireo Health International (CSE: VREO), a leading physician-led, science-focused multi-state cannabis company, today announced that patients living in the New York City metro area, Westchester County, and Nassau County now have access to free, same-day marijuana delivery.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Launched in April 2017, Vireo’s medical marijuana home delivery service has rapidly expanded. Since its inception, the Company has made more than 25,000 home deliveries to patients. With over 1,000 Google reviews with an average 4.9 out of 5 star rating, it is now the first company in New York to offer a free same-day delivery option.

“Our same-day home delivery service is designed to match the convenience that New Yorkers have become accustomed to in the era of Amazon, Uber and Seamless,” said Founder and Chief Executive Officer, Kyle Kingsley, M.D.  “The growing popularity of our home delivery service has allowed us to achieve the economies of scale necessary to offer same-day delivery throughout the Greater New York City area.”

Vireo’s home delivery service was designed by a team of security experts, pharmacists, and health-care providers. “As a physician-led company, our goal is to provide safe and effective products in a trusted and supportive environment, and nothing is safer than one’s own home. We want to ensure that all our patients do not feel stigmatized and can receive the highest quality service and products with the convenience they deserve,” said Stephen Dahmer, M.D., Chief Medical Officer of Vireo Health.

Patients who place orders by 12:00 p.m. EDT will be eligible to receive free same-day delivery. Payment for deliveries can be made using CanPay, a cannabis debit payment app available on iPhone and Android devices. More information is available online at www.vireohealth.com/ny/delivery.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-launches-new-yorks-first-same-day-marijuana-delivery-service-300885679.html

SOURCE Vireo Health International, Inc.

Posted on

Wuhan Provides Updates on Corporate, Psilocybin and Cannabis Q3 2019 Milestones

CAPE TOWN, South Africa, July 02, 2019 (GLOBE NEWSWIRE) — via NetworkWire — Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to share the following statements and coming milestones:

Statements

  • The company would like to clarify for all past, current and potential future shareholders that Wuhan General Group is a US-registered corporation and has no dealings with any Chinese parties as it relates to its ongoing business activities. To remove any possible confusion with its current name and to better reflect the nature of the business, the Company has retained the services of a law firm to specifically take all necessary steps to file a name change with FINRA. Once approved, the company will issue a press release to inform shareholders.
  • The Company is currently investigating all options regarding an up-listing and becoming a fully reporting issuer. Wuhan will share more information as it becomes available.
  • The Company last month closed on the purchase of 49% of Biodelta Nutraceuticals, Ltd. (“Biodelta”) assets at a cost price of $USD1.567 Million financed by private funding. No shares have been issued for this transaction. Biodelta Nutraceuticals, Ltd. assets which include the land, buildings, and the infrastructure as well as the specialized greenhouse and drying ovens. These assets will be part of our new operational facility located near Cape Town, South Africa. This transaction enables Wuhan to produce 36,000 kg of Cannabis in phase one (300k sq. ft) which is ready to grow, and 175,000 kg (1.3M sq. ft) in phase 2, planned for later this year. The acquisition will allow Wuhan to produce a very high-end organic pharmaceutical grade CBD, eliminating the risk of shortage as well as being cost-efficient.

Milestones

  • Biodelta Nutraceuticals has been contracted to support the Company’s wholly-owned subsidiary, MJ MedTech Inc. to develop, brand, market and commercialize its internationally trademarked Dr. AnnaRx™. The Company is planning to have its first Dr. AnnaRx™ line of CBD based products in stores this month and expand across South Africa in more than 1,000 pharmacies in the following weeks.

    List of products this month:

  1. Dr. AnnaRx exclusive line of CBD infused beauty and health products: Day Cream, Night Cream, Serum, Shampoo, Conditioner, UV Sun Protector.
  2. Medspresso™, an exclusive line of CBD infused espresso and coffee in capsule format. The flavors offered are Tanzanian Peaberry, light, medium and dark roast, and decaf coffee.
  • The Company has retained the services of a law firm to work on the cancellation of 19,844,398 shares of WUHN Common Stock held by Fame Good International Limited previously issued under past management. Wuhan strongly believes that the shares were issued inappropriately and will be canceled and returned to the treasury. After cancellation, the outstanding shares count would be 22.4 million shares. A 47% reduction of the current outstanding shares counts of 42.2 million shares. Another positive step in enhancing shareholder value.
  • The Company is delighted to witness US cities decriminalizing mushrooms containing the psychedelic psilocybin, also known as “magic mushrooms“. Wuhan anticipates this trend to continue not only in the US but globally. M2BIO was specifically set up to be a leader in the field of research and commercialization of medicines derived from mushrooms containing psilocybin. Wuhan believes the mushroom sector as it develops will have as much if not more potential market size than the cannabis sector. More information regarding international joint venture and partnership will be available once finalized.
  • Wuhan, Biodelta, and ARC are currently working out the details for a comprehensive memorandum of understanding (MOU) as it relates to cannabis and mushrooms. The Agricultural Research Council (ARC) is the premier science institution in the southern hemisphere that conducts research with partners, develops human capital and fosters innovation to support and develop the agricultural sector.  Much more on this very powerful partnership will be released via a Company press release.

About Biodelta Nutraceuticals

Biodelta Nutraceuticals (ISO 22000 and organic certified) is a Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa. For the past 12 years, Biodelta has developed, designed and produced more than 1,000 products for these customers and is now strategically positioned to launch CBD products through these channels. In addition, Biodelta has license applications in the progress for growing, extracting and product development as well as dossiers for various CBD based products.

For further information contact:

Website: https://biodelta.net/

Public Relations E-mail: info@biodelta.net

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

 

Primary Logo

Posted on

Vireo Health Announces Inclusion in Horizons Marijuana Index ETFs

MINNEAPOLIS, June 27, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR).

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

The Horizons US Marijuana Index (HMUS) was the first of its kind and seeks to track the price movements of a portfolio of North American publicly listed companies with significant business activities in the United States marijuana or hemp industries. Stocks must meet certain requirements to be included in this ETF. A company must be listed on an US or Canadian exchange, represent significant exposure in the hemp and marijuana industries, have a market capitalization greater than CAD$75M, a stock price greater than CAD$0.25, and have a 30 day average daily trading volume of greater than CAD$100,000. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than 10.0 percent of the weight in the index.

The Horizons Emerging Marijuana Growers Index (HMJR) is designed to provide exposure to the performance of a basket of primarily North American publicly listed small-capitalization companies primarily involved in the cultivation, production and/or distribution of marijuana. Stocks must meet certain requirements to be included in this ETF. A company must be listed on a regulated stock exchange in a developed market; be a cultivator, producer, and/or distributor of marijuana or cannabis; and have a market capitalization greater than CAD$50M. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than eight percent of the weight in the index.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven states and territories: Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico and Rhode Island. For more information about the company, please visit www.vireohealth.com.

Contact Information 

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-announces-inclusion-in-horizons-marijuana-index-etfs-300876102.html

SOURCE Vireo Health International, Inc.